413 related articles for article (PubMed ID: 25728680)
1. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Gui Y; Yeganeh M; Donates YC; Tobelaim WS; Chababi W; Mayhue M; Yoshimura A; Ramanathan S; Saucier C; Ilangumaran S
Oncogene; 2015 Nov; 34(46):5718-28. PubMed ID: 25728680
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.
Gui Y; Khan MGM; Bobbala D; Dubois C; Ramanathan S; Saucier C; Ilangumaran S
World J Gastroenterol; 2017 Sep; 23(36):6639-6649. PubMed ID: 29085209
[TBL] [Abstract][Full Text] [Related]
3. Regulation of MET receptor signaling by SOCS1 and its implications for hepatocellular carcinoma.
Gui Y; Yeganeh M; Cepero-Donates Y; Ramanathan S; Saucier C; Ilangumaran S
Curr Pharm Des; 2014; 20(17):2922-33. PubMed ID: 23944359
[TBL] [Abstract][Full Text] [Related]
4. SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes.
Gui Y; Yeganeh M; Ramanathan S; Leblanc C; Pomerleau V; Ferbeyre G; Saucier C; Ilangumaran S
J Hepatol; 2011 Dec; 55(6):1300-8. PubMed ID: 21703184
[TBL] [Abstract][Full Text] [Related]
5. Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver.
Yeganeh M; Gui Y; Kandhi R; Bobbala D; Tobelaim WS; Saucier C; Yoshimura A; Ferbeyre G; Ramanathan S; Ilangumaran S
Oncogene; 2016 Aug; 35(32):4200-11. PubMed ID: 26725321
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
7. SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
Villalobos-Hernandez A; Bobbala D; Kandhi R; Khan MG; Mayhue M; Dubois CM; Ferbeyre G; Saucier C; Ramanathan S; Ilangumaran S
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):36-47. PubMed ID: 27779203
[TBL] [Abstract][Full Text] [Related]
8. SILAC proteomics implicates SOCS1 in modulating cellular macromolecular complexes and the ubiquitin conjugating enzyme UBE2D involved in MET receptor tyrosine kinase downregulation.
Santharam MA; Shukla A; Ihsan AU; Cloutier M; Levesque D; Ramanathan S; Boisvert FM; Ilangumaran S
Biochimie; 2021 Mar; 182():185-196. PubMed ID: 33493533
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma.
Khan MGM; Ghosh A; Variya B; Santharam MA; Ihsan AU; Ramanathan S; Ilangumaran S
BMC Cancer; 2020 Aug; 20(1):774. PubMed ID: 32807134
[TBL] [Abstract][Full Text] [Related]
10. SPTBN1 inhibits inflammatory responses and hepatocarcinogenesis via the stabilization of SOCS1 and downregulation of p65 in hepatocellular carcinoma.
Lin L; Chen S; Wang H; Gao B; Kallakury B; Bhuvaneshwar K; Cahn K; Gusev Y; Wang X; Wu Y; Marshall JL; Zhi X; He AR
Theranostics; 2021; 11(9):4232-4250. PubMed ID: 33754058
[No Abstract] [Full Text] [Related]
11. Epigenetic downregulation of the suppressor of cytokine signaling 1 (Socs1) gene is associated with the STAT3 activation and development of hepatocellular carcinoma induced by methyl-deficiency in rats.
Bagnyukova TV; Tryndyak VP; Muskhelishvili L; Ross SA; Beland FA; Pogribny IP
Cell Cycle; 2008 Oct; 7(20):3202-10. PubMed ID: 18843197
[TBL] [Abstract][Full Text] [Related]
12. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis.
Yan XL; Jia YL; Chen L; Zeng Q; Zhou JN; Fu CJ; Chen HX; Yuan HF; Li ZW; Shi L; Xu YC; Wang JX; Zhang XM; He LJ; Zhai C; Yue W; Pei XT
Hepatology; 2013 Jun; 57(6):2274-86. PubMed ID: 23316018
[TBL] [Abstract][Full Text] [Related]
14. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways.
Wu JR; Hu CT; You RI; Ma PL; Pan SM; Lee MC; Wu WS
PLoS One; 2015; 10(1):e0114495. PubMed ID: 25607934
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular carcinoma.
Liu L; Li W; Wei X; Cui Q; Lou W; Wang G; Hu X; Qian C
Gene Ther; 2013 Jan; 20(1):84-92. PubMed ID: 22318090
[TBL] [Abstract][Full Text] [Related]
16. Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus.
Strebovsky J; Walker P; Lang R; Dalpke AH
FASEB J; 2011 Mar; 25(3):863-74. PubMed ID: 21084693
[TBL] [Abstract][Full Text] [Related]
17. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
18. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2.
Hu CT; Cheng CC; Pan SM; Wu JR; Wu WS
Cell Signal; 2013 Jun; 25(6):1457-67. PubMed ID: 23524339
[TBL] [Abstract][Full Text] [Related]
19. ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression.
Jang JY; Jeon YK; Lee CE; Kim CW
Int J Oncol; 2013 Feb; 42(2):574-82. PubMed ID: 23242177
[TBL] [Abstract][Full Text] [Related]
20. SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET.
He Q; Lin Z; Wang Z; Huang W; Tian D; Liu M; Xia L
Oncogene; 2020 Dec; 39(50):7279-7295. PubMed ID: 33046796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
